The 7MM Opioid Withdrawal Syndrome (OWS) market held a market value of USD 1,068.3 Million in 2021 and is forecasted to reach USD 2,633.4 Million by the year 2030. The market is anticipated to register a CAGR of 10.4% over the projected period.
Opioid withdrawal syndrome occurs when a person suddenly withdraws or reduces their heavy or prolonged consumption of opioids. The symptoms include anxiety, nausea, drug craving, vomiting, diarrhoea, increased heart rate, restless legs, and sweating, among others.
Various clinical trials are going on, which are expected to create various opportunities in the market. For instance, a study titled “Randomized control trial of buprenorphine vs morphine for the treatment of neonatal opioid withdrawal syndrome (NOWS)”. The study is in its phase 3 trials and the trials are being conducted in the Women and Infants Hospital, Providence, Rhode Island, the U.S. Increasing cases of opioid addiction coupled with the rising engagement by private & public institutions are anticipated to boost the market growth. Despite the driving factors, adverse effects of opioids are expected to hinder the market growth during the forecast period.
Increasing cases of opioid addiction
According to the World Health Organization, as of August 2021, approximately 0.5 million people die suffering from drug abuse globally. It also stated that 70% of these deaths are due to opioids and out of these 30% are due to its overdose. Prolonged use, non-medical uses, use without medical supervision, and misuse are leading to opioid dependence and causing various health issues. Therefore, increasing cases of opioid addiction are expected to boost the market growth.
The 7MM Opioid Withdrawal Syndrome (OWS) market is segmented based on therapy.
The buprenorphine segment is expected to account for more than 50% of the market share in 2021 owing to its increasing usage due to its high demand as it works in low or moderate doses as well. The lucemyra (lofexidine) segment is anticipated to grow at the fastest growth rate of 13.6% owing to its easy availability and growing focus of market players for distribution of this drug.
Based on region, the 7MM Opioid Withdrawal Syndrome (OWS) market consists of the U.S., EU5, and Japan, EU5 is further divided into the UK, Germany, France, Italy, and Spain.
The U.S. market is expected to witness a CAGR of 11.1% during the forecast period, which is more than the overall 7MM marketplace CAGR. This is owing to the growing opioid addiction in the country. In the U.S., the diagnosis and therapeutics rate of OWS is continuously increasing. The major factors leading to the increasing prevalence of chronic diseases, which is leading to the rise in the adoption of opioids for pain management. Moreover, the leading market players, such as Indivior, generates majority of the revenue from the United States market.
Within the Japanese market, Naltrexone is estimated to witness the highest growth rate of 9.1% over the forecast period due to the presence of a large number of Naltrexone manufacturers in the country. Total prevalent cases of OWS in Japan was 37,223 in 2015 and 38,602 in 2019.
In the EU5 region, based on therapy, France is estimated to account for a market size of over USD 50 million by 2021 owing to the rising awareness regarding opioid withdrawal syndrome and its treatment options. Furthermore, within Spain, the buprenorphine segment accounted for the largest market share of around 40% in 2021, due to its widespread availability. In Italy, the total treatable cases of OWS was 16,614 in 2015 and 13,866 in 2019. Similarly, in Germany, the total diagnosed OWS cases in Germany was 45,505 in 2015 and 51,114 in 2019.
The US Worldmeds LLC manufactures and markets Lucemyra, which is a non-opioid prescription medicine for treatment of opioid withdrawal symptoms. The product is under license from Britannia Pharmaceuticals, Ltd. The US Worldmeds LLC (USWM, LLC) is an exclusive distributor and licensee of Lucemyra in the U.S. and its territories.
Emerging therapies in the market are by Indivior Plc, Alkermes, Chiesi Farmaceutici S.p.A., Aphios Corporation, Biodelivery Sciences International Inc., Tital Pharmaceuticals, and other prominent players.
Opioid withdrawal syndrome occurs when a person suddenly withdraws or reduces their heavy or prolonged consumption of opioids. The symptoms include anxiety, nausea, drug craving, vomiting, diarrhoea, increased heart rate, restless legs, and sweating, among others.
Various clinical trials are going on, which are expected to create various opportunities in the market. For instance, a study titled “Randomized control trial of buprenorphine vs morphine for the treatment of neonatal opioid withdrawal syndrome (NOWS)”. The study is in its phase 3 trials and the trials are being conducted in the Women and Infants Hospital, Providence, Rhode Island, the U.S. Increasing cases of opioid addiction coupled with the rising engagement by private & public institutions are anticipated to boost the market growth. Despite the driving factors, adverse effects of opioids are expected to hinder the market growth during the forecast period.
Growth Influencers:
Increasing cases of opioid addiction
According to the World Health Organization, as of August 2021, approximately 0.5 million people die suffering from drug abuse globally. It also stated that 70% of these deaths are due to opioids and out of these 30% are due to its overdose. Prolonged use, non-medical uses, use without medical supervision, and misuse are leading to opioid dependence and causing various health issues. Therefore, increasing cases of opioid addiction are expected to boost the market growth.
Segments Overview:
The 7MM Opioid Withdrawal Syndrome (OWS) market is segmented based on therapy.
By Therapy
- Lucemyra (Lofexidine)
- Methadone
- Buprenorphine
- Naltrexone
- Others (Britlofex, Masimo Bridge, etc.)
The buprenorphine segment is expected to account for more than 50% of the market share in 2021 owing to its increasing usage due to its high demand as it works in low or moderate doses as well. The lucemyra (lofexidine) segment is anticipated to grow at the fastest growth rate of 13.6% owing to its easy availability and growing focus of market players for distribution of this drug.
Regional Overview
Based on region, the 7MM Opioid Withdrawal Syndrome (OWS) market consists of the U.S., EU5, and Japan, EU5 is further divided into the UK, Germany, France, Italy, and Spain.
The U.S. market is expected to witness a CAGR of 11.1% during the forecast period, which is more than the overall 7MM marketplace CAGR. This is owing to the growing opioid addiction in the country. In the U.S., the diagnosis and therapeutics rate of OWS is continuously increasing. The major factors leading to the increasing prevalence of chronic diseases, which is leading to the rise in the adoption of opioids for pain management. Moreover, the leading market players, such as Indivior, generates majority of the revenue from the United States market.
Within the Japanese market, Naltrexone is estimated to witness the highest growth rate of 9.1% over the forecast period due to the presence of a large number of Naltrexone manufacturers in the country. Total prevalent cases of OWS in Japan was 37,223 in 2015 and 38,602 in 2019.
In the EU5 region, based on therapy, France is estimated to account for a market size of over USD 50 million by 2021 owing to the rising awareness regarding opioid withdrawal syndrome and its treatment options. Furthermore, within Spain, the buprenorphine segment accounted for the largest market share of around 40% in 2021, due to its widespread availability. In Italy, the total treatable cases of OWS was 16,614 in 2015 and 13,866 in 2019. Similarly, in Germany, the total diagnosed OWS cases in Germany was 45,505 in 2015 and 51,114 in 2019.
Marketed and Emerging Therapies
The US Worldmeds LLC manufactures and markets Lucemyra, which is a non-opioid prescription medicine for treatment of opioid withdrawal symptoms. The product is under license from Britannia Pharmaceuticals, Ltd. The US Worldmeds LLC (USWM, LLC) is an exclusive distributor and licensee of Lucemyra in the U.S. and its territories.
Emerging therapies in the market are by Indivior Plc, Alkermes, Chiesi Farmaceutici S.p.A., Aphios Corporation, Biodelivery Sciences International Inc., Tital Pharmaceuticals, and other prominent players.
The 7MM Opioid Withdrawal Syndrome (OWS) market report provides insights on the below pointers:
- Market Penetration: Provides comprehensive information on the market offered by the prominent players
- Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
- Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the 7MM Opioid Withdrawal Syndrome (OWS) market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
- Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
- Unmet Needs: Non-Opioid, Broader Access, Label to Guide Usage, Safe & Effective
- Opioid Withdrawal Syndrome (OWS): Disease Background & Overview: Introduction; Signs & Symptoms; Cause & Clinical Features of OWS; Etiology, Epidemiology, & Genetics of OWS; Pathophysiology; OWS Diagnosis
- Case Reports
- Epidemiology: The U.S., EU5, Japan. Details are covered under following heads for 7MM - Assumptions & Rationale, Key Insights, Total Prevalent Cases of OWS.
- Clinical Trials Assessment: Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS); CHF6563 in Babies with Neonatal Opioid Withdrawal Syndrome; Opioids Withdrawal Syndrome in Critically Ill Patients: A Multicenter Prospective Cohort Study; +40 more
- Treatment Algorithm, Current Treatment, and Medical Practices: The American Society of Addiction Medicine-approved medications for opioid addiction treatment are listed in Table - Mild withdrawal; Intense withdrawal; Current treatment; Medical Practices
- Proposed Guidelines for OWS
The 7MM Opioid Withdrawal Syndrome (OWS) market report answers questions such as:
- What is the market size and forecast of the 7MM Opioid Withdrawal Syndrome (OWS) Market?
- What are the inhibiting factors and impact of COVID-19 on the 7MM Opioid Withdrawal Syndrome (OWS) Market during the assessment period?
- Which are the products/segments/applications/areas to invest in over the assessment period in the 7MM Opioid Withdrawal Syndrome (OWS) Market?
- What is the competitive strategic window for opportunities in the 7MM Opioid Withdrawal Syndrome (OWS) Market?
- What are the technology trends and regulatory frameworks in the 7MM Opioid Withdrawal Syndrome (OWS) Market?
- What is the market share of the leading players in the 7MM Opioid Withdrawal Syndrome (OWS) Market?
- What modes and strategic moves are considered favorable for entering the 7MM Opioid Withdrawal Syndrome (OWS) Market?
Table of Contents
Chapter 1. Key InsightsChapter 2. Executive Summary of Opioid Withdrawal Syndrome (OWS)
Chapter 3. Opioid Withdrawal Syndrome (OWS): Market Overview at a Glance
Chapter 4. Opioid Withdrawal Syndrome (OWS): Disease Background and Overview
Chapter 5. Case Reports
Chapter 6. Epidemiology and Patient Population
Chapter 7. United States Epidemiology
Chapter 8. EU5 Epidemiology
Chapter 9. Japan Epidemiology
Chapter 10. Treatment Algorithm, Current Treatment, and Medical Practices
Chapter 11. Proposed Guidelines for OWS
Chapter 12. Unmet Needs
Chapter 13. Marketed Therapies
Chapter 14. Emerging Therapies
Chapter 15. Opioid Withdrawal Syndrome (OWS): 7MM Market Analysis
Chapter 16. United States: Market Outlook
Chapter 17. EU-5 countries: Market Outlook
Chapter 18. Japan Market Outlook
Chapter 19. Clinical Trial Assessment
Chapter 20. Market Drivers
Chapter 21. Market Barriers
Chapter 22. SWOT Analysis
Chapter 23. Appendix -Research Methodology
Chapter 24. Publisher Capabilities
Chapter 25. Disclaimer
Chapter 26. About the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aphios Corporation
- Chiesi Farmaceutici S.p.A.
- Titan Pharmaceuticals, Inc.
- BioDelivery Sciences International, Inc.
- Alkermes
- Indivior PLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 159 |
| Published | November 2021 |
| Forecast Period | 2021 - 2030 |
| Estimated Market Value ( USD | $ 1068.3 Million |
| Forecasted Market Value ( USD | $ 2633.4 Million |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
